At present, the most successful anti-inflammatory drugs for atherosclerosis are canakinumab, colchicine, etc., whose mechanisms focus on the different levels of the NLRP3 inflammasome pathway, including the downstream pathway of NLRP3: IL-18/IL-1β and the downstream pathway of IL-1: IL-6 (4). Here, NLRP3 is linked to atherosclerosis.